Trials / Completed
CompletedNCT02583919
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes
Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS-GCGRRx- Dose Level 1 | once weekly dosing for 26 weeks |
| DRUG | ISIS-GCGRRx- Dose Level 2 | once weekly dosing for 26 weeks |
| DRUG | Placebo | once weekly dosing for 26 weeks |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-12-15
- Completion
- 2017-05-11
- First posted
- 2015-10-22
- Last updated
- 2018-06-25
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02583919. Inclusion in this directory is not an endorsement.